BNN — BRAIN Biotech AG Income Statement
0.000.00%
Last trade - 00:00
- €32.66m
- €33.87m
- €56.23m
- 30
- 37
- 15
- 15
R2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 40 | 39.1 | 39.2 | 50.3 | 56.2 |
Cost of Revenue | |||||
Gross Profit | 22.6 | 22 | 22.4 | 28.2 | 31 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 47.2 | 47.3 | 45.8 | 55.9 | 61.7 |
Operating Profit | -7.2 | -8.23 | -6.55 | -5.65 | -5.48 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.1 | -9.94 | -4.28 | -6.17 | -7.49 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.1 | -9.02 | -4.68 | -6.34 | -8.11 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -11.1 | -9.68 | -4.97 | -6.59 | -8.28 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.1 | -9.68 | -4.97 | -6.59 | -8.28 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.451 | -0.391 | -0.267 | -0.307 | -0.371 |
Dividends per Share |